<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555733</url>
  </required_header>
  <id_info>
    <org_study_id>E2006-J086-014</org_study_id>
    <nct_id>NCT04555733</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants</brief_title>
  <official_title>An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lemborexant in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the pharmacokinetics (PK) of lemborexant and&#xD;
      metabolites (M4, M9, and M10) in plasma in healthy Chinese participants following single and&#xD;
      multiple oral doses of lemborexant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-8h): Area Under the Concentration-time Curve From Zero Time to 8 Hours Postdose for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-8 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24h): Area Under the Concentration-time Curve From Zero Time to 24 Hours Postdose for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-24 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t): Area Under the Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf): Area Under the Concentration-time Curve From Zero Time Extrapolated to Infinite Time for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz: Terminal Phase Rate Constant for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t½: Terminal Elimination Phase Half-life for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT: Mean Residence Time for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution at Terminal Phase for Lemborexant Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F: Apparent Total Clearance Following Extravascular Administration for Lemborexant Following Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite to Lemborexant Area Under the Concentration-time Curve From Zero Time Extrapolated to Infinite Time Ratio Following Molecular Weight Correction to Lemborexant Equivalents After Single Dose in All Cohorts</measure>
    <time_frame>All Cohorts, Day 1: 0-240 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose (Day 15 dosing) in Cohort 2</measure>
    <time_frame>Cohort 2, Day 15: 0-24 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose (Day 15 dosing) in Cohort 2</measure>
    <time_frame>Cohort 2, Day 15: 0-24 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-8h): Area Under the Concentration-time Curve From Zero Time to 8 Hours Postdose for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose (Day 15 dosing) in Cohort 2</measure>
    <time_frame>Cohort 2, Day 15: 0-8 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24h): Area Under the Concentration-time Curve From Zero Time to 24 Hours Postdose for Lemborexant and Its Metabolites (M4, M9, and M10) Following Single Dose (Day 15 dosing) in Cohort 2</measure>
    <time_frame>Cohort 2, Day 15: 0-24 hours post single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-8h): Area Under the Concentration-time Curve From Zero Time to 8 Hours Postdose for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses (Day 28 dosing) in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-8 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-τ): Area Under the Concentration-time Curve Over the Dosing Interval for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,avg: Average Steady State Concentration for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,max: Maximum Observed Concentration at Steady State for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Css,min: Minimum Observed Concentration at Steady State for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PTF: Peak-trough Fluctuation for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tss,max: Time to Reach the Maximum Plasma Concentration (Cmax) for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses at Steady State in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz: Terminal Phase Rate Constant for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t½: Terminal Elimination Phase Half-life for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT: Mean Residence Time for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F: Apparent Volume of Distribution at Terminal Phase for Lemborexant Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLss/F: Apparent Total Clearance Following Extravascular Administration at Steady-state for Lemborexant Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rac: Accumulation Ratio for Lemborexant and Its Metabolites (M4, M9, and M10) Following Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite to Lemborexant Area Under the Concentration-time Curve Over the Dosing Interval Ratio Following Molecular Weight Correction to Lemborexant Equivalents After Multiple Doses in Cohort 2</measure>
    <time_frame>Cohort 2, Day 28: 0-324 hours post multiple dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Lemborexant 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of lemborexant 5 milligram (mg) tablet, orally on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Lemborexant 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1 followed by a washout period of approximately 14 days further followed by multiple doses of lemborexant 10 mg tablets, orally, once daily from Day 15 through Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Lemborexant 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of lemborexant 25 mg (1*5 mg tablet and 2*10 mg tablet), orally on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lemborexant</intervention_name>
    <description>Lemborexant oral tablets.</description>
    <arm_group_label>Cohort 1: Lemborexant 5 mg</arm_group_label>
    <arm_group_label>Cohort 2: Lemborexant 10 mg</arm_group_label>
    <arm_group_label>Cohort 3: Lemborexant 25 mg</arm_group_label>
    <other_name>E2006</other_name>
    <other_name>Dayvigo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Chinese adult male or female participants living in China.&#xD;
&#xD;
          2. Non-smoking, age greater than or equal to (&gt;=) 18 years and less than or equal to (&lt;=)&#xD;
             45 years old at the time of obtaining written consent. To be considered non-smokers,&#xD;
             participant must have discontinued smoking for at least 4 weeks before first dosing.&#xD;
&#xD;
          3. Participants with a body mass index (BMI) of 19 to 24 kilogram per square meter&#xD;
             (kg/m^2) at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who weigh less than 50 kilogram (kg) at Screening.&#xD;
&#xD;
          2. Females who are breastfeeding or pregnant (as documented by a positive beta-human&#xD;
             chorionic gonadotropin [β-hCG] test with a minimum sensitivity of International units&#xD;
             per liter (IU/L) or equivalent units of β-hCG). A separate baseline assessment is&#xD;
             required if a negative screening pregnancy test was obtained more than 72 hours before&#xD;
             the first dose of study drug.&#xD;
&#xD;
          3. Females of childbearing potential who:&#xD;
&#xD;
             a. Within 28 days before study entry, did not use a highly effective method of&#xD;
             contraception, which includes any of the following:&#xD;
&#xD;
             i. total abstinence (if it is their preferred and usual lifestyle)&#xD;
&#xD;
             ii. an intrauterine device or intrauterine hormone-releasing system (IUS)&#xD;
&#xD;
             iii. a contraceptive implant&#xD;
&#xD;
             iv. an oral contraceptive except for contraceptives containing levonorgestrel (with&#xD;
             additional barrier method) (Participant must be on a stable dose of the same oral&#xD;
             contraceptive product for at least 28 days before dosing and throughout the study and&#xD;
             for 28 days after study drug discontinuation.)&#xD;
&#xD;
             v. have a vasectomized partner with confirmed azoospermia.&#xD;
&#xD;
             b. Do not agree to use a highly effective method of contraception (as described above)&#xD;
             throughout the entire study period and for 28 days after study drug discontinuation.&#xD;
&#xD;
             It is permissible that if a highly effective method of contraception is not&#xD;
             appropriate or acceptable to the participant, then the participant must agree to use a&#xD;
             medically acceptable method of contraception, that is, double-barrier methods of&#xD;
             contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap&#xD;
             with spermicide.&#xD;
&#xD;
             NOTE: All females will be considered to be of childbearing potential unless they are&#xD;
             postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age&#xD;
             group, and without other known or suspected cause) or have been sterilized surgically&#xD;
             (that is, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all&#xD;
             with surgery at least 1 month before dosing).&#xD;
&#xD;
          4. Clinically significant illness that requires medical treatment within 8 weeks or a&#xD;
             clinically significant infection that requires medical treatment within 4 weeks before&#xD;
             first dosing.&#xD;
&#xD;
          5. Evidence of disease that may influence the outcome of the study within 4 weeks before&#xD;
             first dosing; example psychiatric disorders and disorders of the gastrointestinal&#xD;
             tract, liver, kidney, respiratory system, endocrine system, hematological system,&#xD;
             neurological system, or cardiovascular system, or participants who have a congenital&#xD;
             abnormality in metabolism.&#xD;
&#xD;
          6. Any suicidal ideation with intent to act with or without a plan at screening or within&#xD;
             6 months of screening.&#xD;
&#xD;
          7. Any suicidal behavior within 10 years of screening.&#xD;
&#xD;
          8. Any history of gastrointestinal surgery that may affect PK profiles of lemborexant,&#xD;
             example, hepatectomy, digestive organ resection at screening.&#xD;
&#xD;
          9. Any clinically abnormal symptom or organ impairment based on medical history, physical&#xD;
             examination, vital signs, electrocardiogram (ECG) or laboratory test results, which&#xD;
             require medical treatment.&#xD;
&#xD;
         10. A prolonged QT/QTc interval (QT interval corrected for heart rate by Fridericia's&#xD;
             formula [QTcF] greater than (&gt;) 450 milliseconds [ms]) as demonstrated by a repeated&#xD;
             ECG.&#xD;
&#xD;
         11. Known history of clinically significant drug allergy at Screening.&#xD;
&#xD;
         12. Known history of food allergy or presently experiencing significant seasonal or&#xD;
             perennial allergy at Screening.&#xD;
&#xD;
         13. Human immunodeficiency virus (HIV) positive demonstrated by positive serology at&#xD;
             Screening.&#xD;
&#xD;
         14. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening.&#xD;
&#xD;
         15. History of drug or alcohol dependency or abuse within 2 years before Screening, or a&#xD;
             positive urine drug test or breathe alcohol test.&#xD;
&#xD;
         16. Participants who contravene the restrictions on concomitant medications, food and&#xD;
             beverages during the Screening Period.&#xD;
&#xD;
         17. Currently enrolled in another clinical study or used any investigational drug or&#xD;
             device within 28 days or 5 half-lives, whichever is longer, preceding informed&#xD;
             consent.&#xD;
&#xD;
         18. Receipt of blood products within 4 weeks, or donation of blood or plasma within 3&#xD;
             months before first dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Phase 1</keyword>
  <keyword>E2006</keyword>
  <keyword>Healthy Participants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lemborexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

